Does Rallies show Form 4 insider transactions for NVCR?

Yes. Rallies tracks NVCR insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is NVCR research on Rallies investment advice?

No. Rallies provides research, data, and educational context for NVCR. It does not provide personalized investment advice.

NVCR (NovoCure Limited Ordinary Shares) Stock Analysis - Insider Trades

NovoCure Limited Ordinary Shares (NVCR) is a publicly traded Healthcare sector company. As of May 21, 2026, NVCR trades at $17.60 with a market cap of $2.02B and a P/E ratio of -14.46. NVCR moved +4.29% today. Year to date, NVCR is +28.90%; over the trailing twelve months it is -2.47%. Its 52-week range spans $9.82 to $34.13. Analyst consensus is buy with an average price target of $26.17. Rallies surfaces NVCR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading NVCR stock inside the company?

Recent NVCR insider activity includes Paravasthu Mukund sold 43.25K, Leupin Nicolas sold 1.10K, Weinberg Uri sold 6.41K, Brackmann Christoph sold 6.41K, and Leonard Frank X sold 5.61K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

NVCR Key Metrics

Key financial metrics for NVCR
Metric	Value
Price	$17.60
Market Cap	$2.02B
P/E Ratio	-14.46
EPS	$-1.22
Dividend Yield	0.00%
52-Week High	$34.13
52-Week Low	$9.82
Volume	29
Avg Volume	0
Revenue (TTM)	$655.35M
Net Income	$-136.23M
Gross Margin	74.54%

Recent NVCR Insider Trades

Paravasthu Mukund sold 43.25K (~$595.67K) on Mar 5, 2026.
Leupin Nicolas sold 1.10K (~$14.64K) on Mar 4, 2026.
Weinberg Uri sold 6.41K (~$85.31K) on Mar 4, 2026.
Brackmann Christoph sold 6.41K (~$85.31K) on Mar 4, 2026.
Leonard Frank X sold 5.61K (~$74.60K) on Mar 4, 2026.

Latest NVCR News

Japan Grants National Insurance Reimbursement for Optune Lua NSCLC Treatment — Mar 9, 2026
NovoCure Q4 Loss Narrows to $0.22 EPS, Beats Estimates — Feb 26, 2026
Novocure’s Optune Pax Approved by FDA for Locally Advanced Pancreatic Cancer — Feb 25, 2026
Novocure Gains 37% on Pancreatic Cancer Device Clearance; Soleus Boosts Celcuity Stake — Feb 13, 2026
Novocure’s Optune Pax FDA Approval Boosts Pancreatic Cancer Survival by Two Months — Feb 12, 2026

NVCR Analyst Consensus

6 analysts cover NVCR: 0 strong buy, 4 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $26.17.

Common questions about NVCR

Who is trading NVCR stock inside the company?: Recent NVCR insider activity includes Paravasthu Mukund sold 43.25K, Leupin Nicolas sold 1.10K, Weinberg Uri sold 6.41K, Brackmann Christoph sold 6.41K, and Leonard Frank X sold 5.61K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for NVCR?: Yes. Rallies tracks NVCR insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is NVCR research on Rallies investment advice?: No. Rallies provides research, data, and educational context for NVCR. It does not provide personalized investment advice.